Head-to-head · free
Amphastar Pharmaceuticals, Inc. vs Alibaba Group Holding Limited
AMPH vs BABA — return on capital, cash generation, margins and balance sheet side by side.
AMPH
7 / 10
measures where AMPH leads
BABA
3 / 10
measures where BABA leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | AMPH · FY2025 | BABA · FY2026 |
|---|---|---|
| Revenue | $719.9M | $1.02T |
| Net income | $98.1M | $103.6B |
| Revenue growth (yearly, multi-year) | 13.2% | 4.7% |
| Free cash flow | $121.2M | (50.7B) |
| Free cash flow margin | 16.8% | -5.0% |
| Net cash / (debt) | — | (86.1B) |
| ROIC | 7.9% | 2.8% |
| Return on equity | 12.9% | 10.0% |
| Gross margin | 49.5% | 39.8% |
| Operating margin | 19.5% | 5.8% |
| Net debt / EBITDA | 2.16x | 1.32x |
Figures are as reported by each company; latest fiscal year shown.
Where Amphastar Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $34.9M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Alibaba Group Holding Limited's cash went (FY2026)
- Capital spending
- $126.9B
- Buybacks
- $7.6B
- Dividends
- $33.7B
- Acquisitions
- $12.1B
- Net debt issued / (repaid)
- $39.0B
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free